Business Services

Pharmaceutical Business Services – News, analysis and company profiles

Showing 15 posts of 2454 posts found.

PHARMANOVIA ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH AETERNA ZENTARIS FOR THE FIRST AND ONLY ORALLY ADMINISTERED APPROVED MEDICINE FOR THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS

March 16, 2023 Business Services

BASILDON, UK, 16 MARCH 2023 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the …

Zolgensma®▼ (onasemnogene abeparvovec) receives NICE final draft guidance in presymptomatic babies up to 12 months with spinal muscular atrophy (SMA)

March 16, 2023 Business Services

 London, UK, 16th March 2023 – Novartis Gene Therapies has confirmed that the National Institute for Health and Care Excellence …

Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology

March 16, 2023 Business Services

Boston, Massachusetts, March 16th, 2023 – Aldena Therapeutics Inc. (Aldena) a private biotech company pioneering siRNA-based therapies for dermatological indications, …

DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine

March 15, 2023 Business Services

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish drug delivery and drug development company, today announces that …

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

March 14, 2023 Business Services

Hong Kong, Shanghai & Florham Park, NJ — Tuesday, March 14, 2023: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that, further …

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

March 14, 2023 Business Services

AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the …

Acesion Pharma announces positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint achieved

March 14, 2023 Business Services

14 March 2023, Copenhagen, Denmark – Acesion Pharma (“Acesion”), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation (“AF”), the …

EP0042 receives Orphan Drug Designation from the US Food and Drug Administration

March 14, 2023 Business Services

 Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

March 14, 2023 Business Services

Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from …

Newron announces 2022 financial results and provides outlook for 2023

March 14, 2023 Business Services

Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company …

Cell and Gene Therapy Catapult opens new Process Analytical Technologies laboratory

March 14, 2023 Business Services

London, 14 March 2023: The Cell and Gene Therapy Catapult (CGT Catapult) today announces the opening of a new laboratory …

Scottish patients with the most aggressive form of viral hepatitis become first in UK to be offered routine NHS access to Hepcludex® (bulevirtide)

March 14, 2023 Business Services

Monday 13 March 2023, London, UK – Gilead Sciences Ltd today announced that the Scottish Medicines Consortium (SMC) has become …

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

March 13, 2023 Business Services

KANSAS CITY, KANSAS and PRINCETON, NEW JERSEY – March 13, 2023 – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing …
The Gateway to Local Adoption Series

Latest content